SELLAS Life Sciences Presents Immunobiological And Clinical Data From Phase 1/2 Trial Of Galinpepimut-S In Combination With Keytruda In WT1+ Platinum-Resistant Advanced Ovarian Cancer At International Gynecologic Cancer Society 2023 Annual Global Meeting
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences presented data from a Phase 1/2 trial of Galinpepimut-S in combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting. The combination treatment showed a median overall survival of 18.4 months, compared to 13.8 months in a Keytruda single agent study and 11-14 months with standard of care chemotherapy. The combination also yielded a WT1-specific T-cell immune response and correlated positively in a subset of patients with IFNγ and MIP1β biomarkers.
November 06, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keytruda, a product of Merck & Co., was used in combination with Galinpepimut-S in a Phase 1/2 trial for advanced ovarian cancer, showing promising results.
The positive results from the trial where Keytruda was used in combination with Galinpepimut-S could potentially boost Merck & Co.'s stock in the short term as it indicates the effectiveness of their product in combination treatments.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
SELLAS Life Sciences' combination treatment of Galinpepimut-S and Keytruda showed promising results in a Phase 1/2 trial for advanced ovarian cancer.
The positive results from the Phase 1/2 trial of Galinpepimut-S in combination with Keytruda could potentially boost SELLAS Life Sciences' stock in the short term as it indicates progress in their product development and potential future revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100